Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Travere Therapeutics Buyback Yield % Related Terms
Travere Therapeutics Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Travere Therapeutics's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TVTX vs ORKA, DNTH, SRRK: Buyback Yield % Comparison
For the Biotechnology subindustry, Travere Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Travere Therapeutics Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Travere Therapeutics's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Travere Therapeutics's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Travere Therapeutics (TVTX) has a Buyback Yield % of 0.00 as of Aug. 22, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Travere Therapeutics and its competitors. According to the industry distribution chart, Travere Therapeutics ranks #999999 out of 709 companies in the Biotechnology industry.
Is Travere Therapeutics' Buyback Yield % too high?
Travere Therapeutics' current Buyback Yield % is 0.00. Based on the distribution chart, Travere Therapeutics ranks #999999 out of 709 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Travere Therapeutics has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Travere Therapeutics' Buyback Yield % compare to ORKA and DNTH?
According to the Biotechnology industry distribution chart, Travere Therapeutics ranks #999999 out of 709 companies for Buyback Yield %. This places Travere Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Travere Therapeutics and its competitors. Travere Therapeutics's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Travere Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Travere Therapeutics (TVTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $36.75, compared to a current price of $65.71 — trading 78.8% above its estimated fair value. The current Buyback Yield % is 0.00. Travere Therapeutics' overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Travere Therapeutics (TVTX), the current Buyback Yield % is 0.00 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Travere Therapeutics (TVTX) Overvalued in 2026?
Based on GuruFocus' analysis, Travere Therapeutics stock appears to be overvalued.
The current stock price of $65.71 is trading 78.8% above its estimated GF Value™ of $36.75.
GuruFocus considers Travere Therapeutics to be Significantly Overvalued.
Key valuation signals for TVTX:
Buyback Yield %: 0.00
GF Value™: $36.75 vs. price of $65.71 (78.8% above fair value)
No single metric tells the full story. See the TVTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
61GF Score
Get the complete analysis for TVTX
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TVTX has been successfully added to your 
